Physician profile
Dwayne C Miller
NPI 1316957574
$11,274.91
in general payments reported to CMS, 2019-2025
52 companies · $923 in 2025
The $923 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,531 · 2020: $1,341 · 2021: $1,385 · 2022: $1,828 · 2023: $1,751 · 2024: $1,516 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,275.32 | 2019-2025 | Krystexxa, Evenity, Otezla |
| Btg International INC. | $979.60 | 2019 | |
| Horizon Therapeutics Plc | $853.46 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $762.64 | 2019-2025 | Rexulti |
| Abbvie INC. | $759.81 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $691.08 | 2019-2025 | Farxiga, Tezspire, Breztri |
| Lilly USA, LLC | $533.44 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $530.07 | 2019-2024 | Trelegy Ellipta, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $431.10 | 2020-2025 | Jardiance |
| Novo Nordisk INC | $426.81 | 2019-2025 | Ozempic, Rybelsus |
| Allergan, INC. | $337.15 | 2019-2020 | |
| Astellas Pharma US INC | $335.32 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $320.12 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $305.67 | 2019-2024 | Xifaxan |
| Eisai INC. | $273.09 | 2020-2024 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwayne Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.